The objective of this retrospective study is to evaluate the postoperative clinical outcomes at discharge, 1 month and 12 months, associated with the use of Parietex™ ProGrip™ in Laparoscopic Transabdominal preperitoneal inguinal hernia repair. Results from this study will be used to support the short- and long-term clinical outcomes of Parietex™ ProGrip™ when used in inguinal hernia repair by laparoscopic approach. * Single center study * Population: All subjects have undergone Laparoscopic Transabdominal preperitoneal surgical treatment for inguinal hernia repair with Parietex™ ProGrip™ without additional fixation between September 2008 and March 2010 (inclusive) with at least 12 months of follow-up. The primary outcome: • Proportion of subjects who experience hernia recurrence (defect treated initially with Parietex™ ProGrip™) within 12 months post-surgery. Recurrence is defined as a clinically manifest bulge or a protrusion exacerbated by a Valsalva maneuver in the operated groin. The recurrence symptoms are assessed by phone based on the Symptoms Questionnaire and the recurrence diagnosis is confirmed during a physical examination by a physician and defined as a clinically manifest bulge or a protrusion exacerbated by a Valsalva maneuver in the operated groin. If subject has a surgical repair of the hernia within the 12 month postoperative period, it will be documented as evidence of hernia recurrence. The secondary outcome: * Incidence of Groin Pain (pain score 0-10) and analgesic use at discharge, 1 month and 12 month postoperatively * Incidence of postoperative complications including, wound infection (any infection of the incision), mesh infection (an infection of the mesh), bleeding, mesh migration, mesh erosion, fistula, small bowel obstruction, seroma, hematuria, hematoma, inflammation, chronic pains/ inguinodynia, infection, visceral adherence, allergic reactions to the components of the product at discharge, 1month and 12 month post-operatively * Patient satisfaction * Operative time * Hospital length of stay
Study Type
OBSERVATIONAL
Enrollment
200
Evangelisches Krankenhaus Zweibrücken - Obere Himmelsbergstr. 38
Zweibrücken, Germany
Proportion of Subjects Who Experience Hernia Recurrence (Defect Treated Initially With Parietex™ ProGrip™) Within 12 Months Post-surgery.
Recurrence is defined as a clinically manifest bulge or a protrusion exacerbated by a Valsalva maneuver in the operated groin. The recurrence symptoms are assessed by phone based on the Symptoms Questionnaire and the recurrence diagnosis is confirmed during a physical examination by a physician.
Time frame: At least 12 months post-surgery
Incidence of Groin Pain (Pain Score 0-10)
Time frame: 12 month post-operatively
Analgesic Use
Time frame: The day of the discharge (an expected average of 1 day), 1month and at least 12 month post-operatively
Postoperative Complications Including, Infection, Seroma, Hematoma, Visceral Adherence, Allergy Etc
Time frame: up to 12 months
Patient Satisfaction
Time frame: at least 12 month post-operatively
Operative Time
Time frame: From skin incision to closure (The expected median operating time is 36 minutes for unilateral and 50 minutes for bilateral repair)
Hospital Length of Stay
Time frame: Duration of the hospital stay (expected average of 1 day)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.